{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:19:05Z","timestamp":1791314345093,"version":"4.3.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":2761,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1093\/annonc\/mdr573","type":"journal-article","created":{"date-parts":[[2012,1,21]],"date-time":"2012-01-21T05:08:26Z","timestamp":1327122506000},"page":"1085-1094","source":"Crossref","is-referenced-by-count":29,"title":["Recent developments in treatments targeting castration-resistant prostate cancer bone metastases"],"prefix":"10.1016","volume":"23","author":[{"given":"Y.","family":"Loriot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr573_bb0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 7","key":"10.1093\/annonc\/mdr573_bb0020","doi-asserted-by":"crossref","first-page":"vii91","DOI":"10.1093\/annonc\/mdn473","article-title":"Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer","volume":"19","author":"Sternberg","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0025","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","article-title":"Prostate cancer bone metastases promote both osteolytic and osteoblastic activity","volume":"91","author":"Keller","year":"2004","journal-title":"J Cell Biochem"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdr573_bb0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdr573_bb0045","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.urolonc.2007.11.004","article-title":"Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond","volume":"26","author":"Smith","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0055","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1093\/annonc\/mdr573_bb0060","unstructured":"NCCN. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prostate Cancer, V4.2011. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp (July 2011, date last accessed)."},{"key":"10.1093\/annonc\/mdr573_bb0065","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr573_bb0070","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr573_bb0075","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr573_bb0080","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr573_bb0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2009.11.005","article-title":"SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer","volume":"36","author":"Saad","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdr573_bb0090","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0095","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1200\/JCO.2005.03.0841","article-title":"Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype","volume":"23","author":"Loberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/jcb.20522","article-title":"A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions","volume":"96","author":"Loberg","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1093\/annonc\/mdr573_bb0105","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0110","doi-asserted-by":"crossref","first-page":"6296s","DOI":"10.1158\/1078-0432.CCR-06-0929","article-title":"Targeting bone metastasis in prostate cancer with endothelin receptor antagonists","volume":"12","author":"Carducci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0115","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/0008-5472.CAN-03-1382","article-title":"Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein","volume":"64","author":"Dai","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0120","first-page":"2587","article-title":"Prostate cancer cells-osteoblast interaction shifts expression of growth\/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts","volume":"9","author":"Fizazi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0125","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1432-0436.2002.700905.x","article-title":"Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting","volume":"70","author":"Sung","year":"2002","journal-title":"Differentiation"},{"key":"10.1093\/annonc\/mdr573_bb0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"The role of bisphosphonates in breast and prostate cancers","volume":"11","author":"Brown","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0135","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdr573_bb0140","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0145","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr573_bb0150","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr573_bb0155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0160","series-title":"Zometa (Zoledronic acid) US Prescribing Information","author":"Novartis","year":"2011"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdr573_bb0165","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ctrv.2008.03.006","article-title":"Antitumor effects of bisphosphonates: promising preclinical evidence","volume":"34","author":"Guise","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdr573_bb0170","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1464-4096.2004.04831.x","article-title":"Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation","volume":"94","author":"Coxon","year":"2004","journal-title":"BJU Int"},{"key":"10.1093\/annonc\/mdr573_bb0175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2004.04.022","article-title":"Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer","volume":"46","author":"Montague","year":"2004","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdr573_bb0180","first-page":"1089","article-title":"Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells","volume":"29","author":"Tanaka","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2407-8-81","article-title":"Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice","volume":"8","author":"Tuomela","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0190","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/1078-0432.CCR-05-2050","article-title":"The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model","volume":"12","author":"Yang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/0284186X.2010.482103","article-title":"Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines","volume":"50","author":"Epplen","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cellbi.2008.11.011","article-title":"Docetaxel\/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells","volume":"33","author":"Karabulut","year":"2009","journal-title":"Cell Biol Int"},{"key":"10.1093\/annonc\/mdr573_bb0205","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/0008-5472.CAN-04-3601","article-title":"Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer","volume":"65","author":"Kim","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0210","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/02841860600996447","article-title":"The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer","volume":"46","author":"Morgan","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0215","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/02841860510029617","article-title":"Additive\/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid","volume":"44","author":"Ullen","year":"2005","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2407-6-15","article-title":"Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment","volume":"6","author":"Brubaker","year":"2006","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdr573_bb0225","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ctrv.2008.03.008","article-title":"Emerging role of bisphosphonates in the clinic\u2014antitumor activity and prevention of metastasis to bone","volume":"34","author":"Lipton","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdr573_bb0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1479-5876-2-16","article-title":"Endothelin receptors as novel targets in tumor therapy","volume":"2","author":"Bagnato","year":"2004","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdr573_bb0235","first-page":"663","article-title":"Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer","volume":"56","author":"Nelson","year":"1996","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0240","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.1830978100","article-title":"A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases","volume":"100","author":"Yin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdr573_bb0245","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/cbt.8.8.7922","article-title":"Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles","volume":"8","author":"Weydert","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdr573_bb0250","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4161\/cbt.9.8.11112","article-title":"Bone-specific growth inhibition of prostate cancer metastasis by atrasentan","volume":"9","author":"Drake","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdr573_bb0255","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1593\/neo.06388","article-title":"Endothelin receptor A blockade enhances taxane effects in prostate cancer","volume":"8","author":"Akhavan","year":"2006","journal-title":"Neoplasia"},{"key":"10.1093\/annonc\/mdr573_bb0260","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/0008-5472.CAN-06-3879","article-title":"In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer","volume":"67","author":"Banerjee","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0265","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CAD.0b013e328320791c","article-title":"Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054","volume":"20","author":"Growcott","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdr573_bb0270","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1464-410X.2009.08740.x","article-title":"Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer","volume":"104","author":"Fizazi","year":"2009","journal-title":"BJU Int"},{"key":"10.1093\/annonc\/mdr573_bb0275","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0280","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0285","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/cncr.23864","article-title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0290","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1158\/1078-0432.CCR-08-1085","article-title":"A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer","volume":"14","author":"Armstrong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0295","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10637-009-9318-5","article-title":"A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer","volume":"29","author":"Schelman","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdr573_bb0300","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"55","author":"James","year":"2009","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdr573_bb0305","author":"Southwest Oncology Group","year":"2011","journal-title":"S0421 Closes Early; Interim Analysis Finds No Benefit in Adding Atrasentan to Prostate Chemotherapy"},{"key":"10.1093\/annonc\/mdr573_bb0310","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.117","article-title":"Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC)","volume":"29","author":"Nelson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0315","author":"AstraZeneca Global","year":"2011","journal-title":"AstraZeneca Halts Phase III Trial of ZIBOTENTAN in Non-metastatic Castrate Resistant Prostate Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.23998","article-title":"Targeting Src signaling in metastatic bone disease","volume":"124","author":"Araujo","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0325","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","article-title":"Src kinases as therapeutic targets for cancer","volume":"6","author":"Kim","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0330","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1093\/annonc\/mdr573_bb0335","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/13543781003789388","article-title":"Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer","volume":"19","author":"Edwards","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1093\/annonc\/mdr573_bb0340","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/annonc\/mdm086","article-title":"The role of Src in prostate cancer","volume":"18","author":"Fizazi","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0345","doi-asserted-by":"crossref","first-page":"17660","DOI":"10.1074\/jbc.M311032200","article-title":"Src kinase activity is essential for osteoclast function","volume":"279","author":"Miyazaki","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdr573_bb0350","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/1078-0432.CCR-08-1857","article-title":"SRC family kinase activity is up-regulated in hormone-refractory prostate cancer","volume":"15","author":"Tatarov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0355","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","article-title":"Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells","volume":"65","author":"Nam","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0360","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1158\/0008-5472.CAN-07-2997","article-title":"Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model","volume":"68","author":"Park","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0365","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.4161\/cbt.8.22.9770","article-title":"Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation","volume":"8","author":"Araujo","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdr573_bb0370","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/leu.2008.237","article-title":"Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor","volume":"23","author":"Brownlow","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdr573_bb0375","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/onc.2010.73","article-title":"Src family kinase\/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts","volume":"29","author":"Lee","year":"2010","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdr573_bb0380","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/leu.2008.356","article-title":"Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdr573_bb0385","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/jbmr.85","article-title":"The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo","volume":"25","author":"Vandyke","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdr573_bb0390","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bjc.6605178","article-title":"Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis","volume":"101","author":"Koreckij","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0395","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1038\/onc.2008.250","article-title":"Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530","volume":"27","author":"Chang","year":"2008","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdr573_bb0400","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/0008-5472.CAN-08-0442","article-title":"Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0405","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/1541-7786.MCR-08-0219","article-title":"The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts","volume":"7","author":"de Vries","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0410","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-09-0962","article-title":"SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis","volume":"9","author":"Rabbani","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdr573_bb0415","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":"Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdr573_bb0420","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1359\/jbmr.090830","article-title":"Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial","volume":"25","author":"Hannon","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdr573_bb0425","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/CAD.0b013e328325a867","article-title":"A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study","volume":"20","author":"Lara","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdr573_bb0430","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/10428190802005191","article-title":"Thalidomide and lenalidomide: mechanism-based potential drug combinations","volume":"49","author":"Vallet","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdr573_bb0435","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bmc.2003.11.007","article-title":"Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer","volume":"12","author":"Capitosti","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.1093\/annonc\/mdr573_bb0440","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/mdr573_bb0445","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","article-title":"Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1","volume":"107","author":"Anderson","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr573_bb0450","first-page":"129","article-title":"Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation","volume":"33","author":"Munemasa","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0455","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2004.05.074","article-title":"Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer","volume":"22","author":"Dahut","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0460","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2009.25.4524","article-title":"Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Ning","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0465","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0091270009335001","article-title":"Phase I study of oral lenalidomide in patients with refractory metastatic cancer","volume":"49","author":"Dahut","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdr573_bb0470","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00280-009-1237-9","article-title":"A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy","volume":"65","author":"Mathew","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdr573_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdr573_bb0480","first-page":"386","article-title":"Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma","volume":"147","author":"Humphrey","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdr573_bb0485","doi-asserted-by":"crossref","first-page":"293s","DOI":"10.1200\/jco.2011.29.15_suppl.4516","article-title":"Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from phase II randomized discontinuation trial","volume":"29","author":"Hussain","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0490","first-page":"249","article-title":"Dosage and response in radiopharmaceutical therapy of painful osseous metastases","volume":"37","author":"Silberstein","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/mdr573_bb0495","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","article-title":"Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial","volume":"357","author":"Tu","year":"2001","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr573_bb0500","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","article-title":"Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0505","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0510","doi-asserted-by":"crossref","first-page":"318s","DOI":"10.1200\/jco.2011.29.15_suppl.4620","article-title":"Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223","volume":"29","author":"Nilsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdr573_bb0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(11)70100-9","article-title":"Overall survival benefit of radium-223 chloride (Alpharadin\u2122) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA)","volume":"47","author":"Parker","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdr573_bb0520","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdr573_bb0525","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdr573_bb0530","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr573_bb0535","series-title":"Xvega\u2122 Prescribing Information (US)","author":"Amgen","year":"2010"},{"key":"10.1093\/annonc\/mdr573_bb0540","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr573_bb0545","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0550","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr573_bb0555","doi-asserted-by":"crossref","unstructured":"Tollefson MK, Karnes RJ, Thompson RH et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. In ASCO Genitourinary Cancers Symposium, San Francisco, CA. (Abstr 168). 2010.","DOI":"10.1016\/j.juro.2010.02.1055"},{"key":"10.1093\/annonc\/mdr573_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0045(19980401)35:1<1::AID-PROS1>3.0.CO;2-O","article-title":"Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo","volume":"35","author":"Borgstrom","year":"1998","journal-title":"Prostate"},{"key":"10.1093\/annonc\/mdr573_bb0565","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.eururo.2008.01.082","article-title":"Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study","volume":"54","author":"Di Lorenzo","year":"2008","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdr573_bb0570","doi-asserted-by":"crossref","first-page":"951s","DOI":"10.1200\/jco.2010.28.18_suppl.lba4511","article-title":"A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401","volume":"28","author":"Kelly","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0575","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2008.05.007","article-title":"Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts","volume":"270","author":"Cumashi","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdr573_bb0580","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/annonc\/mdp323","article-title":"Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy","volume":"21","author":"Sonpavde","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0585","first-page":"292s","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC)","volume":"29","author":"Michaelson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr573_bb0590","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-10-1863","article-title":"Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis","volume":"16","author":"Russell","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341934709X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341934709X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/5\/1085\/487242\/mdr573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:26:43Z","timestamp":1624440403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341934709X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S092375341934709X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr573","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}